ctrl K

Watchlist Price Alert

Gracell Biotechnologies I... (GRCL)

NASDAQ: GRCL · Real-Time Price · USD

10.25

0.01 (0.05%)

At close: Feb 21, 2024, 9:00 PM

Gracell Biotechnologies Income Statement

Financials in CNY. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	n/a	366K	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	366K	n/a	n/a	n/a
Operating Income	-624.66M	-463.57M	-214.4M	-146.58M	-62.5M
Interest Income	23.92M	9.12M	2.87M	3.93M	1.44M
Pretax Income	-607.49M	-451.75M	-211.9M	-138.66M	-60.79M
Net Income	-607.51M	-465.88M	-197.16M	-132.18M	-60.79M
Selling & General & Admin	139.27M	137.04M	45.57M	27.36M	10.26M
Research & Development	485.39M	326.9M	168.83M	119.22M	52.24M
Other Expenses	8.16M	9.06M	4.7M	1.43M	276K
Operating Expenses	624.66M	463.94M	214.4M	146.58M	62.5M
Interest Expense	6.74M	5.06M	2.15M	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	624.66M	463.94M	214.4M	146.58M	62.5M
Income Tax Expense	22K	14.13M	-14.74M	-6.49M	1.71M
Shares Outstanding (Basic)	21.5M	13.15M	13.11M	3.96M	3.96M
Shares Outstanding (Diluted)	21.5M	13.15M	13.11M	3.96M	3.96M
EPS (Basic)	-28.25	-35.4	-15.05	-33.35	-15.35
EPS (Diluted)	-28.25	-35.4	-15.05	-33.35	-15.35
EBITDA	-592.58M	-385.13M	-206.83M	-144.01M	-57.8M
EBIT	-600.75M	-446.69M	-209.75M	n/a	n/a
Depreciation & Amortization	32.08M	78.45M	7.57M	2.57M	2.99M